Biotech firm Moderna recently announced that it would never enforce the patent on its COVID-19 vaccine in 92 countries currently receiving the shots through a global program. It’s the first major pharmaceutical company to announce such a move, which critics say came later than it should have and which opens the door to wide-scale global production. Under CEO Stéphane Bancel, Moderna is also developing mRNA vaccines targeting 15 pathogens that are more common in the developing world, as well as longtime public-health threats such as influenza and RSV.
A weekly newsletter featuring conversations with the world’s top CEOs, managers, and founders. Join the Leadership Brief.
More Must-Reads from TIME
- Welcome to the Noah Lyles Olympics
- Melinda French Gates Is Going It Alone
- What to Do if You Can’t Afford Your Medications
- How to Buy Groceries Without Breaking the Bank
- Sienna Miller Is the Reason to Watch Horizon
- Why So Many Bitcoin Mining Companies Are Pivoting to AI
- The 15 Best Movies to Watch on a Plane
- Want Weekly Recs on What to Watch, Read, and More? Sign Up for Worth Your Time